REGENERON PHARMACEUTICALS, INC. - FORM 10-K - EX-23.1 - CONSENT OF PRICEWATERHOUSECOOPERS LLP - February 17, 2011

Attached files

file filename
10-K - ANNUAL REPORT - REGENERON PHARMACEUTICALS, INC.regeneron_10k.htm
EX-31.2 - CERTIFICATION OF CFO PURSUANT TO RULE 13A-14(A) - REGENERON PHARMACEUTICALS, INC.exhibit31-2.htm
EX-31.1 - CERTIFICATION OF CEO PURSUANT TO RULE 13A-14(A) - REGENERON PHARMACEUTICALS, INC.exhibit31-1.htm
EX-10.1.8 - FORM OF OPTION AGREEMENT AND RELATED NOTICE OF GRANT - REGENERON PHARMACEUTICALS, INC.exhibit10_1-8.htm
EX-10.1.7 - FORM OF RESTRICTED STOCK AWARD AGREEMENT AND RELATED NOTICE OF GRANT - REGENERON PHARMACEUTICALS, INC.exhibit10_1-7.htm
EX-10.11.7 - SEVENTH AMENDMENT TO LEASE - REGENERON PHARMACEUTICALS, INC.exhibit10_11-7.htm
EXCEL - IDEA: XBRL DOCUMENT - REGENERON PHARMACEUTICALS, INC.Financial_Report.xls
EX-32 - CERTIFICATION OF CEO AND CFO PURSUANT TO 18 U.S.C. SECTION 1350 - REGENERON PHARMACEUTICALS, INC.exhibit32.htm

Exhibit 23.1
 
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
 
We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-61132, 333-97375, 333-119257, 333-151941, and 333-169569) and on Form S-3 (No. 333-169786) of Regeneron Pharmaceuticals, Inc., of our report dated February 17, 2011 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.
 
 
 
/s/ PricewaterhouseCoopers LLP
 
New York, New York
February 17, 2011
 

REGENERON PHARMACEUTICALS, INC. Reports

Also read